Terminal differentiation and mitogen-activated protein kinase signaling in human cholesteatoma epithelium

Otology and Neurotology

Volumn 27, Issue 3, 2006, Pages 422-426

  Huisman, Margriet A ^a   De Heer, Emile ^a   Grote, Jan J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

p38; pERK1 2; pJNK

Indexed keywords

INVOLUCRIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; CHOLESTEATOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM CELL; EUKARYOTIC CELL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CASE-CONTROL STUDIES; CELL CYCLE; CELL DIFFERENTIATION; CHOLESTEATOMA, MIDDLE EAR; EPITHELIUM; HUMANS; IMMUNOHISTOCHEMISTRY; MAP KINASE KINASE 4; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN PRECURSORS; SIGNAL TRANSDUCTION;

EID: 33646830447     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/00129492-200604000-00021     Document Type: Article

References (20)

1. Olszewska E, Wagner M, Bernal-Sprekelsen M, et al. Etiopathogenesis of cholesteatoma. Eur Arch Otorhinolaryngol 2004;261:6-24.
2. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40.
3. Efimova T, LaCelle P, Welter JF, Eckert RL. Regulation of human involucrin promoter activity by a protein kinase C, Ras, MEKK1, MEK3, p38/RK, AP1 signal transduction pathway. Biol Chem 1998;273:24387-95.
4. Johansen C, Kragballe K, Westergaard M, Henningsen J, Kristiansen K, Iversen L. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 2005;152:37-42.
5. Takahashi H, Ibe M, Nakamura S, Ishida-Yamamoto A, Hashimoto Y, Iizuka H. Extracellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis. J Dermatol Sci 2002;30:94-9.
6. Hazelbag HM, v.d. Broek LJCM, van Dorst EBL, Offerhaus JA, Fleuren GJ, Hogendoorn PCW. Immunostaining of chain-specific keratins on formalin-fixed, paraffin-embedded tissues: a comparison of various antigen retrieval systems using microwave heating and proteolytic treatments. J Histochem Cytochem 1995;43:429-37.
7. Jacobs JJ, Lehe C, Cammans KD, Yoneda K, Das PK, Elliott GR. An automated method for the quantification of immunostained human Langerhans cells. J Immunol Methods 2001;247:73-82.
8. Eckert RL, Crish JF, Efimova T, et al. Regulation of involucrin gene expression. J Invest Dermatol 2004;123:13-22.
9. Efimova T, Broome AM, Eckert RL. A regulatory role for p38 delta MAPK in keratinocyte differentiation: evidence for p38 delta-ERK1/2 complex formation. J Biol Chem 2003;278:34277-85.
10. Rosdy M. Opposite effects of EGF on involucrin accumulation of A431 keratinocytes and a variant which is not growth-arrested by EGF. In Vitro Cell Dev Biol 1988;24:1127-32.
11. Stammberger M, Bujia J, Kastenbauer E. Alterationof epidermal differentiation in middle ear cholesteatoma. AmJ Otol 1995;16:527-31.
12. Wan YS, Wang ZQ, Voorhees J, Fisher G. EGF receptor crosstalks with cytokine receptors leading to the activation of c-Jun kinase in response to UV irradiation in human keratinocytes. Cell Signal 2001;13:139-44.
13. Ishida-Yamamoto A, Iizuka H. Differences in involucrin immunolabeling within cornified cell envelopes in normal and psoriatic epidermis. J Invest Dermatol 1995;104:391-5.
14. Iizuka H, Takahashi H, Ishida-Yamamoto A. Psoriatic architecture constructed by epidermal remodeling. J Dermatol Sci 2004;35:93-9.
15. Jost M, Huggett TM, Kari C, Rodeck U. Matrix-independent survival of human keratinocytes through an EGF receptor/MAPK-kinase-dependent pathway. Mol Biol Cell 2001;12:1519-27.
16. Manohar A, Shome SG, Lamar J, et al. Alpha 3 beta 1 integrin promotes keratinocyte cell survival through activation of a MEK/ ERK signaling pathway. J Cell Sci 2004;117:4043-54.
17. Bernal Sprekelsen M, Ebmeyer J, Anonopoulos A, Borkowski G, Sudhoff H. Alterations of the basal membrane in middle ear cholesteatoma. Acta Otorrinolaringol Esp 2001;52:330-5.
18. Albino AP, Kimmelman CP, Parisier SC. Cholesteatoma: a molecular and cellular puzzle. Am J Otol 1998;19:7-19.
19. Huisman MA, De Heer E, Grote JJ. Sustained extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signalling is related to increased p21 expression in cholesteatoma epithelium. Acta Otolaryngol 2005;125:134-40.
20. Huisman MA, De Heer E, Grote JJ. Cholesteatoma epithelium is characterized by increased expression of Ki-67, p53 and p21, with minimal apoptosis. Acta Otolaryngol 2003;123:377-82.